hyperglucagonemia

hyperglucagonemia

 [hi″per-gloo″kah-gon-e´me-ah]
abnormally high levels of glucagon in the blood.

hyperglucagonemia

/hy·per·glu·ca·gon·emia/ (-gloo″kah-gon-e´me-ah) abnormally high levels of glucagon in the blood.

hyperglucagonemia

abnormally high levels of glucagon in the blood.
References in periodicals archive ?
Decrease in [beta]-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig.
As DeFronzo has highlighted, the accelerated lipolysis of fat cells, deficiency in incretin axis, hyperglucagonemia from a-cell hyperactivity, and increased glucose reabsorption in the kidney are all key components in the pathogenesis and progression of T2DM (22).
The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
Apart from insulin resistance, hyperglucagonemia, increased hepatic sensitivity to glucagon, lipotoxicity, and glucotoxicity all enhance hepatic gluconeogenesis.
To the triumvirate, his research has added fat cells, the gastrointestinal tract, hyperglucagonemia, the kidney and the brain as critical factors in diabetes treatment.
Also, it has been noted in the past that the hyperglucagonemia that results when the alpha cells overproduce glucagon has led to pancreas tumors in animal studies, so that's a risk," said Dr.
T2DM is characterized by multiple alterations in glucose homeostasis, including peripheral insulin resistance, pancreatic [beta]-cell dysfunction, reduced insulin secretion, impaired insulin action, hyperglucagonemia, impaired fatty acid metabolism, and diminished amylin effect.
Failure to document hyperglucagonemia in a dog with diabetic dermatopathy resembling necrolytic migratory erythema.
Hyperglucagonemia may disrupt glucose homeostasis through opposing
Although the glucoregulatory effects of noninsulin hormones have been postulated since the 1940s, (5) our ability to pharmacologically manage the alterations in glycemic control resulting from deficient GLP-1 and amylin as well as hyperglucagonemia have only recently become clinically available.